- Company
- Eisai Co., Ltd / Date Established : Dec 6. 1941
- Head Office
- 4-6-10 Koishikawa, Bunkyo-hu, Tokyo 112-8088, Japan(Tel : 81-3-3817-3700)
- Representatives
- Haruo Naito,
Representative Corporate Officer and CEO
- Hideki Hayashi,
Representative Corporate Officer, Corporate Planning & Strategy and CIO
- Yutaka Tsuchiya,
Representative Corporate Officer, Healthcare Policy and China Business
- Hajime Shimizu,
Representative Corporate Officer and CFO
- Hideshi Honda,
Representative Corporate Officer and Asia Region President
- Capital
- 44,985 million Yen (As of March 31, 2014)
- Sales
-
- Consolidated : 600,363 million Yen
- Non-Consolidated : 341,766 million Yen
- (The year ended March 31, 2014)
- Scope of Business
-
- Manufacturing and marketing of prescription medicines and over-the-counter products
- Employees
-
- Consolidated: 10,419
- Non-Consolidated : 4,003 (As of March 31, 2014)
-
- Communication
Offices
- 64 Communication Offices in Japan (As of September 30, 2014)
- Production Plants
- Kawashima Plant (Gifu Prefecture)
- Kashima Business Office (Ibaraki Prefecture)
- Sannova Co., Ltd. (Gunma Prefecture)
- Eisai Inc. North Carolina Plant (U.S.A.)
- Eisai Manufacturing Ltd. (U.K.)
- Eisai China Inc. Suzhou Plant (China)
- Eisai Pharmatechnology & Manufacturing Pvt. Ltd. (India), etc.
- Laboratories
-
- Tsukuba Research Laboratories (Ibaraki Prefecture)
- Kawashima Laboratory (Gifu Prefecture)
- KAN Research Institute Inc. (Hyogo Prefecture)
- Eisai Inc. Andover Research Institute (U.S.A.)
- Morphotek, Inc. (U.S.A.)
- H3 Biomedicine Inc. (U.S.A.)
- Eisai Ltd. Hatfield Research Institute (U.K.), etc.
-
- Overseas Sales
Offices
-
- Eisai Inc. (U.S.A.)
- Eisai Ltd. (U.K.)
- Eisai GmbH (Germany)
- Eisai S.A.S. (France)
- Eisai China Inc. (China)
- Eisai Korea Inc. (South Korea), etc.
-
